Publicaciones científicas

Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).

Galofré JC (1), Santamaría Sandi J (2), Capdevila J (3), Navarro González E (4), Zafón Llopis C (5), Ramón Y Cajal Asensio T (6), Gómez Sáez JM (7), Jiménez-Fonseca P (8), Riesco Eizaguirre G (9), Grande E (10).
(1) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain. Electronic address: jcgalofre@unav.es.
(2) Service of Endocrinology and Nutrition, Hospital Universitario de Cruces, Vizcaya, Spain.
(3) Service of Medical Oncology, Hospital Universitario de la Vall d'Hebron, Barcelona, Spain.
(4) Service of Endocrinology and Nutrition, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
(5) Service of Endocrinology and Nutrition, Hospital Universitario de la Vall d'Hebron, Barcelona, Spain.
(6) Service of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
(7) CIBERDEM Service of Endocrinology and Nutrition, Hospital Universitario de Bellvitge, Spain.
(8) Service of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
(9) Service of Endocrinology and Nutrition, Hospital Universitario de Móstoles, Madrid, Spain.
(10) Service of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain. 

Revista: Endocrinología y Nutrición

Fecha: 26-feb-2015

Área de Patología Tiroidea Endocrinología y Nutrición

BACKGROUND
In Spain medullary thyroid carcinoma (MTC) would not exceed 80 new cases per year and less than half of them would be good candidates for systemic treatment with novel agents.

METHODS
Relevant literature was reviewed, including PubMed searches supplemented with additional articles.

RESULTS
The consensus summarizes the clinical outcomes in terms of activity and toxicity of each of the available drugs. A brief summary of the minimum requirements in terms of follow up and genetic counseling around MTC is also included.

CONCLUSIONS
Only those patients with objective imaging progression in the last 12-14 months with large volume of disease are clear candidates to start systemic treatment. However, those patients with low disease volume should be considered for 'wait and see' strategy until symptoms of the disease appear. Multidisciplinary approach for the management of MTC patient is mandatory nowadays.

CITA DEL ARTÍCULO  Endocrinol Nutr. 2015 Apr;62(4):e37-46. doi: 10.1016/j.endonu.2015.01.005. Epub 2015 Feb 26.

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra